Skip to content
approvedHormone Regulation

Nafarelin

Also known as: Synarel, Nafarelin Acetate

Nafarelin is a synthetic GnRH agonist unique among its class for being administered as a nasal spray rather than by injection. FDA-approved as Synarel for the treatment of endometriosis and central precocious puberty, it provides a non-invasive alternative to injectable GnRH agonists. Like other GnRH agonists, nafarelin initially stimulates and then suppresses the hypothalamic-pituitary-gonadal axis, reducing estrogen to postmenopausal levels. Its intranasal delivery offers a significant quality-of-life advantage for patients, particularly children with precocious puberty, though absorption can be affected by nasal congestion or rhinitis.

3 cited references·5 researched benefits

Quick Answer

Nafarelin (Synarel) is a GnRH agonist delivered as a nasal spray, FDA-approved for endometriosis and central precocious puberty. Unlike injectable GnRH agonists, its intranasal route offers a non-invasive alternative that is especially advantageous for children. It suppresses sex hormones to castrate or postmenopausal levels within 2-4 weeks by downregulating pituitary GnRH receptors after an initial stimulatory flare.

Key Facts

Mechanism
Nafarelin contains a D-naphthylalanine substitution at position 6 of native GnRH, making it approximately 200 times more potent than endogenous GnRH. When administered intranasally, it is absorbed through the nasal mucosa with approximately 2-3% bioavailability. Like other GnRH agonists, initial exposure stimulates LH and FSH release (the flare effect), but continuous administration leads to pituitary GnRH receptor downregulation and desensitization. Within 2-4 weeks, gonadotropin and sex steroid levels are suppressed to castrate/postmenopausal ranges. The intranasal route avoids first-pass metabolism and provides consistent, though lower, bioavailability compared to injectable formulations.
Research Status
approved
Half-Life
~3 hours
Molecular Formula
C₆₆H₈₃N₁₇O₁₃
Primary Use
Hormone Regulation
Table of Contents

Benefits

  • Treats endometriosis with significant pain reduction — FDA-approved with demonstrated efficacy comparable to injectable GnRH agonists in clinical trialsstrong
  • Controls central precocious puberty — effective suppression of pubertal progression with preservation of adult height potentialstrong
  • Non-invasive intranasal delivery — avoids injections entirely, improving adherence and quality of life, especially for pediatric patientsstrong
  • Rapid reversibility — normal menstrual function typically resumes within 4-8 weeks of discontinuationstrong
  • Used in IVF protocols for pituitary downregulation — prevents premature LH surge during controlled ovarian stimulationmoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intranasal spray (endometriosis)200 mcg per spray; 1 spray into one nostril in the morning and 1 spray into the other nostril in the evening (400 mcg/day total)Twice dailyTreatment duration is typically 6 months. If inadequate suppression, dose may be increased to 800 mcg/day (1 spray in each nostril twice daily). Avoid sneezing during or immediately after administration.
Intranasal spray (precocious puberty)800 mcg/day (2 sprays into alternating nostrils, twice daily); may increase to 1,600 mcg/dayTwo to three times dailyHigher doses required in children than for endometriosis. Continued until clinically appropriate age for puberty. Parents should supervise administration.
Intranasal spray (IVF downregulation, off-label)200-400 mcg/dayOnce or twice daily, starting in luteal phaseInitiated on cycle day 21 for pituitary downregulation prior to gonadotropin stimulation. Typically continued until hCG trigger.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Hot flashes — reported in 80-90% of endometriosis patients, the most common side effect of estrogen suppressioncommon
  • Nasal irritation — rhinitis, nasal dryness, and occasional epistaxis (nosebleeds) related to intranasal administrationcommon
  • Headaches — reported in approximately 20% of patientscommon
  • Decreased bone mineral density — 3-6% loss over 6 months of treatment; partially reversible upon discontinuationserious
  • Mood changes and emotional lability — including depression and irritability due to hypoestrogenic statecommon
  • Vaginal dryness and decreased libido — expected effects of postmenopausal estrogen levelscommon
  • Reduced drug absorption during nasal congestion — upper respiratory infections or allergic rhinitis may decrease efficacy; decongestant sprays should be used at least 30 minutes after nafarelinrare

Frequently Asked Questions

How do you use nafarelin nasal spray correctly?
Tilt your head slightly forward, insert the spray tip into one nostril, and spray once while gently inhaling. Alternate nostrils between doses (left nostril in the morning, right in the evening). Do not blow your nose or sniff forcefully for at least 30 minutes after spraying. If you need to use a nasal decongestant, wait at least 30 minutes after nafarelin. The bottle should be stored upright at room temperature and primed before first use.
Does nafarelin cause a hormonal flare like injectable GnRH agonists?
Yes. Like all GnRH agonists, nafarelin produces an initial stimulatory flare of LH, FSH, and sex steroids during the first 1-2 weeks of treatment. For endometriosis patients, this may cause a temporary worsening of symptoms including pelvic pain and spotting. Unlike prostate cancer treatment with injectable GnRH agonists, the flare with nafarelin for endometriosis rarely causes serious clinical complications, but patients should be counseled to expect it.
Can nasal congestion affect nafarelin absorption?
Yes, nasal congestion from colds, allergies, or rhinitis can significantly reduce nafarelin absorption and potentially compromise treatment efficacy. If you develop nasal congestion, contact your healthcare provider. Topical decongestant sprays (oxymetazoline) should be used at least 30 minutes after nafarelin administration to avoid washing away the drug. Patients with chronic rhinitis may be better suited to injectable GnRH agonists.
Is nafarelin as effective as injectable Lupron for endometriosis?
Head-to-head clinical trials have shown nafarelin and leuprolide (Lupron) to be similarly effective for treating endometriosis-associated pain. Both achieve comparable estrogen suppression and symptom relief. The main advantages of nafarelin are non-invasive administration and the ability to self-administer at home without injections. The disadvantages are twice-daily dosing (vs. monthly depot injections), susceptibility to nasal absorption issues, and the need for strict adherence to the dosing schedule.
How long can you use nafarelin for endometriosis?
FDA labeling recommends a maximum of 6 months of nafarelin therapy for endometriosis due to the risk of bone density loss. Retreatment is possible after a recovery period, though cumulative bone loss is a concern. Some clinicians use hormonal add-back therapy (low-dose estrogen-progestin or norethindrone alone) to extend treatment to 12 months while mitigating bone and vasomotor side effects. Any extended use requires periodic bone density monitoring.

References

  1. 1
    Nafarelin for endometriosis: a large-scale, danazol-controlled study of efficacy and safety(1988)PubMed ↗
  2. 2
    Treatment of central precocious puberty with intranasal nafarelin: a randomized trial(1990)PubMed ↗
  3. 3
    Nafarelin versus leuprolide for endometriosis: a comparative clinical trial(1992)PubMed ↗

Latest Research

Last updated: 2026-02-19